UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ANÁLISE DO PERFIL EPIDEMIOLÓGICO E DA EFICÁCIA DO USO DA TERAPIA DUPLA EM PACIENTES HIV DO AMBULATÓRIO DE INFECTOLOGIA DO HOSPITAL SANTA CASA DE MISERICÓRDIA DE VITÓRIA/ES

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.102976, Article 102976

2023

Volltextzugriff (PDF)

MEDICINE AND THE LAW

South African medical journal, 2022-10, Vol.112 (10)

2022

Volltextzugriff (PDF)

RESISTÊNCIA AO DOLUTEGRAVIR EM UM CASO DE TRANSMISSÃO VERTICAL

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.103051

2023

Volltextzugriff (PDF)

SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV NA BAHIA: DADOS DE VIDA REAL

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.103055

2023

Volltextzugriff (PDF)

Dolutegravir-Associated Hyperglycemia in a Patient on Highly Active Antiretroviral Therapies

Nigerian journal of medicine, 2024-09, Vol.32 (6), p.671-673

2024

Volltextzugriff (PDF)

Acute interstitial nephritis due to dolutegravir: The first case reported

Nefrología, 2023-05, Vol.43 (3), p.370-373

2023

Volltextzugriff (PDF)

Camino a una licencia obligatoria para el dolutegravir en Colombia

Salud UIS, 2023, Vol.55 (1)

Rossi, Francisco

2023

Volltextzugriff (PDF)

Synthesis and characterization of two known and one new impurities of dolutegravir: In silico evaluation of certain intermediates against SARS CoV-2 O-ribose methyltransferase (OMTase)

Journal of molecular structure, 2023-01, Vol.1271, p.133992-133992, Article 133992

2023

Volltextzugriff (PDF)

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Clinical infectious diseases, 2021-07, Vol.73 (2), p.e485-e493

2021

Volltextzugriff (PDF)

Investigation of Levan-Derived Nanoparticles of Dolutegravir: A Promising Approach for the Delivery of Anti-HIV Drug as Milk Admixture

Journal of pharmaceutical sciences, 2024-08, Vol.113 (8), p.2513-2523

2024

Volltextzugriff (PDF)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

AIDS (London), 2021-10, Vol.35 (12), p.1957-1965

2021

Volltextzugriff (PDF)

Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction

Antiviral research, 2024-11, Vol.231, p.106020, Article 106020

2024

Volltextzugriff (PDF)

Central nervous system and neuropsychiatric disturbances in people living with HIV

Le infezioni in medicina, 2023, Vol.31 (4)

2023

Volltextzugriff (PDF)

Outcomes of Dolutegravir-Based Antiretroviral Therapy in Thai Youth Aged 18 to 24 Years Living with HIV in Bangkok: A Retrospective Cohort Study

Journal of the Medical Association of Thailand, 2023-10, Vol.106 (10), p.932-942

2023

Volltextzugriff (PDF)

regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa

Pharmacogenomics, 2021-09, Vol.22 (15), p.963-972

2021

Volltextzugriff (PDF)

PERFIL DE PACIENTES EM USO DE TERAPIA DUPLA COM DOLUTEGRAVIR E LAMIVUDINA, COORTE RETROSPECTIVA DE VIDA REAL

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.103038

2023

Volltextzugriff (PDF)

ALTERAÇÃO NO ÍNDICE DE MASSA CORPÓREA (IMC) APÓS SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV ATENDIDOS EM UM SERVIÇO ESPECIALIZADO DE SALVADOR, BAHIA

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.102972

2023

Volltextzugriff (PDF)

ADESÃO EM INDIVÍDUOS COM FALHA VIROLÓGICA INICIAL EM PESSOAS VIVENDO COM HIV QUE INICIARAM A TERAPIA ANTIRRETROVIRAL – COORTE RETROSPECTIVA, BRASIL 2017-2019 (DADOS PRELIMINARES)

The Brazilian journal of infectious diseases, 2023-10, Vol.27, p.102967

2023

Volltextzugriff (PDF)

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy

Clinical infectious diseases, 2020-12, Vol.71 (9), p.e471-e477

2020

Volltextzugriff (PDF)

Real world use of dolutegravir two drug regimens

AIDS (London), 2023-04, Vol.37 (5), p.785-788

2023

Volltextzugriff (PDF)

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable

AIDS (London), 2023-11, Vol.37 (14), p.2131-2136

2023

Volltextzugriff (PDF)

Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection

Mediterranean journal of infection, microbes & antimicrobials, 2022-12, Vol.11 (1)

2022

Volltextzugriff (PDF)

Adverse drug reactions, adherence, and virologic outcomes in adult patients on dolutegravir- based antiretroviral therapy at a tertiary hospital, southeast Nigeria

Ghana medical journal, 2024-03, Vol.58 (1), p.101-108

2024

Volltextzugriff (PDF)

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial

Clinical infectious diseases, 2019-10, Vol.69 (9), p.1498-1505

2019

Volltextzugriff (PDF)

Control over selectivity for demethylation in dolutegravir synthesis in microreactors: Kinetics and mechanisms

Chemical engineering science, 2024-02, Vol.284, p.119453, Article 119453

2024

Volltextzugriff (PDF)

1 – 25 von 1.092

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(942)
Mit Volltextzugriff
(846)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Dolutegravir
(1.008)
Science & Technology
(856)
Life Sciences & Biomedicine
(806)
Hiv
(637)
Humans
(463)
Infectious Diseases
(463)
Human Immunodeficiency Virus
(400)
Hiv Infections - Drug Therapy
(387)
Immunology
(286)
Antiretroviral Drugs
(270)
Antiretroviral Therapy
(254)
Female
(224)
Antiretroviral Agents
(204)
Pharmacology & Pharmacy
(203)
Drug Therapy
(199)
Male
(198)
Adult
(197)
Heterocyclic Compounds, 3-Ring - Therapeutic Use
(169)
Virology
(162)
Highly Active Antiretroviral Therapy
(154)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

ANÁLISE DO PERFIL EPIDEMIOLÓGICO E DA EFICÁCIA DO USO DA TERAPIA DUPLA EM PACIENTES HIV DO AMBULATÓRIO DE INFECTOLOGIA DO HOSPITAL SANTA CASA DE MISERICÓRDIA DE VITÓRIA/ES

MEDICINE AND THE LAW

RESISTÊNCIA AO DOLUTEGRAVIR EM UM CASO DE TRANSMISSÃO VERTICAL

SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV NA BAHIA: DADOS DE VIDA REAL

Dolutegravir-Associated Hyperglycemia in a Patient on Highly Active Antiretroviral Therapies

Acute interstitial nephritis due to dolutegravir: The first case reported

Camino a una licencia obligatoria para el dolutegravir en Colombia

Synthesis and characterization of two known and one new impurities of dolutegravir: In silico evaluation of certain intermediates against SARS CoV-2 O-ribose methyltransferase (OMTase)

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Investigation of Levan-Derived Nanoparticles of Dolutegravir: A Promising Approach for the Delivery of Anti-HIV Drug as Milk Admixture

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction

Central nervous system and neuropsychiatric disturbances in people living with HIV

Outcomes of Dolutegravir-Based Antiretroviral Therapy in Thai Youth Aged 18 to 24 Years Living with HIV in Bangkok: A Retrospective Cohort Study

regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa

PERFIL DE PACIENTES EM USO DE TERAPIA DUPLA COM DOLUTEGRAVIR E LAMIVUDINA, COORTE RETROSPECTIVA DE VIDA REAL

ALTERAÇÃO NO ÍNDICE DE MASSA CORPÓREA (IMC) APÓS SIMPLIFICAÇÃO TERAPÊUTICA COM LAMIVUDINA (3TC) E DOLUTEGRAVIR (DTG) EM PESSOAS VIVENDO COM HIV ATENDIDOS EM UM SERVIÇO ESPECIALIZADO DE SALVADOR, BAHIA

ADESÃO EM INDIVÍDUOS COM FALHA VIROLÓGICA INICIAL EM PESSOAS VIVENDO COM HIV QUE INICIARAM A TERAPIA ANTIRRETROVIRAL – COORTE RETROSPECTIVA, BRASIL 2017-2019 (DADOS PRELIMINARES)

Risk Factors for Weight Gain Following Switch to Integrase Inhibitor–Based Antiretroviral Therapy

Real world use of dolutegravir two drug regimens

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable

Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection

Adverse drug reactions, adherence, and virologic outcomes in adult patients on dolutegravir- based antiretroviral therapy at a tertiary hospital, southeast Nigeria

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial

Control over selectivity for demethylation in dolutegravir synthesis in microreactors: Kinetics and mechanisms

Suchergebnisse filtern